Resveratrol Supplementation Reduces Pain and Inflammation in Knee Osteoarthritis Patients Treated with Meloxicam: A Randomized Placebo-Controlled Study

Abstract

Resveratrol, a polyphenolic compound, is a powerful antioxidant with remarkable anti-inflammatory properties. Inflammation and pain plays an important role in the pathogenesis of knee osteoarthritis (OA) and could cause tissue damage and morbidity. The aim of this study was to evaluate the anti-inflammatory and pain reduction activities of orally administered resveratrol in patients with knee OA. We carried out a 90-day pilot study to evaluate the ability of orally administered resveratrol, as an adjuvant with meloxicam, to decrease knee joint pain and biomarkers of inflammation in comparison with a placebo. One hundred ten men and women (45-75 years old) diagnosed with mild to moderate knee OA were treated with 15 mg per day meloxicam and either 500 mg per day resveratrol or placebo for 90 days in a double-blind, randomized control trial. Pain severity was evaluated at the beginning and at the end of treatment using Visual Analogue Scale-100 scores. Fasting blood was collected to determine serum interleukins 1β and 6, tumor necrosis factor-α, C-reactive protein, and complement proteins C3 and C4. The resveratrol-treated group experienced a time-dependent significant decrease in pain severity (P < .001). Serum levels of the biochemical markers were significantly reduced compared with the placebo-treated group (P < .01). These findings suggest that resveratrol may be an effective "add-on" option with meloxicam in the treatment of patients with mild to moderate knee OA.

Health benefits of resveratrol administration

“…Toniolo et al (2018) observed that supplementation with 0.04% resveratrol for six months also improves the resistance to fatigue and functional-mechanical properties of skeletal muscles in aged mice. Furthermore, resveratrol at a dose of 500 mg per day attenuates joint pain and improves functional activity of patients with knee osteoarthritis (Hussain et al, 2018;Marouf et al, 2018). Farrokhi and others (Farrokhi et al, 2018) demonstrated that 120 µM resveratrol reduced production of matrix metalloproteinase 9, which makes it a potential therapeutic agent in atherosclerosis.…”

The role of sirtuin 1 and its activator, resveratrol in osteoarthritis

“…In a double-blind, randomized control trial which included 110 people with mild-to-moderate knee OA in Iraq, the patient–subjects received 15 mg meloxicam and either 500 mg resveratrol or placebo per day for 90 days. The results showed that the pain severity and serum levels of biochemical markers were significantly decreased in the resveratrol-treated group compared with the placebo-treated group [89]. The study further showed that resveratrol significantly improved function and associated symptoms.…”

Inhibition of Diabetes Mellitus-Induced Knee Joint Injury in Rats by a Combination of Metformin and Captopril

“…diabetes-induced OA. The link between OA and inflammation is well-known (Marouf et al, 2018). To investigate whether the observed protection of OA by Met+cap was also associated with the inhibition of biomarkers of inflammation, we measured hs-CRP, IL-6, and TNF-α in blood samples collected from all animal groups 10 weeks post diabetic induction (Fig.…”